SME Times is powered by   
Search News
Just in:   • Adani Group to invest Rs 57,575 crore in Odisha  • 'Dollar Distancing' finally happening? Time for India to pitch Rupee as credible alternative: SBI Ecowrap  • 49% Indian startups now from tier 2, 3 cities: Jitendra Singh  • 'India ranks 3rd in global startup ecosystem & number of unicorns'  • LinkedIn lays off entire global events marketing team: Report 
Last updated: 27 Sep, 2014  

QPS Expands Phase 1 and Bioanalytical Capability in India

PR Newswire | 26 Jan, 2011

NEWARK, Del. and HYDERABAD, India, Jan. 26, 2011 /PRNewswire/ -- QPS, LLC, a leading full-service GLP/GCP-compliant contract research organization providing testing services to support preclinical and clinical research and development, announced the acquisition of a majority stake in Bioserve Clinical Research. Bioserve, a full service phase 1 CRO headquartered in Hyderabad, India, will be known as QPS-Bioserve India.

QPS is a global CRO supporting drug discovery and development since 1995. Its five areas of expertise include: Preclinical DMPK/Tox, Bioanalytical, Translational Medicine, Early Stage Clinical and Late Stage Clinical Research.

Bioserve is an ISO 9001:2008 certified organization providing world-class clinical research services to sponsors across the globe. Its infrastructure includes a 92-bed clinical unit for conducting phase I studies and a bioanalytical lab equipped with multiple LC/MS/MS systems for small molecule bioanalysis. Over the past 6 years, it has conducted over 500 studies, with numerous product approvals, and has been inspected by the USFDA, UK MHRA, WHO and Indian DCGI.

"This new partnership further expands QPS' global range of linearly integrated services," said Ben Chien, PhD, Chairman, President and CEO of QPS. "With access to Bioserve's additional resources, our customers will have the heightened benefits of a third more phase I beds, bringing our total to 400; greater bioanalytical capacity; and access to another facility, located in India, with a reputation for outstanding performance and a record of timely approvals. Furthermore, current customers will be reassured to learn that Mr. Suneil Reddy will remain as Managing Director."

The company has been growing at a rate of over 50% per year, with a current team of over 100 employees. Clients include large Indian as well as Multinational pharmaceutical firms. Bioserve's promoters - the founders of Vijaya Diagnostic Centre, one of the largest diagnostic health care companies in India - bring a wealth of 30 years experience in the healthcare and clinical domain, combined with a passion for quality.

About QPS

QPS provides GLP/GCP-compliant preclinical and clinical research services to pharmaceutical and biotechnology clients worldwide in the areas of Bioanalysis, Drug Metabolism and Pharmacokinetics, Translational Medicine, and Clinical Research. Founded by Dr. Ben Chien in 1995, QPS has Bioanalysis and Preclinical testing facilities at its Newark, DE headquarters; in Groningen, the Netherlands; and in Taipei, Taiwan. Early-phase clinical facilities are located in Springfield, MO; Taipei, Taiwan; and Groningen, the Netherlands. Business development offices are maintained in the US, Europe, and Asia.

About Bioserve

Bioserve was established in 2004 as a regulatory class CRO, offering end-to-end services, primarily catering to the needs of the generic pharmaceutical industry. Bioserve focuses on sponsors' requirements - quality, compliance, and time and cost effectiveness - while remaining reliable and responsive. Bioserve's services include Phase I & Bioavailability/Bioequivalence studies, PK in Patient Populations, Bioanalytical Services, Statistical & IVIVC Analysis, Pharmacoscintigraphic Imaging, Clinical Trial Management and Regulatory Affairs.

SOURCE QPS, LLC

 
Print the Page Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
66.20
64.50
UK Pound
87.50
84.65
Euro
78.25
75.65
Japanese Yen 58.85 56.85
As on 13 Aug, 2022
  Daily Poll
PM Modi's recent US visit to redefine India-US bilateral relations
 Yes
 No
 Can't say
  Commented Stories
» GIC Re's revenue from obligatory cession threatened(1)
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter